Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Merck's Keytruda Secures First FDA-Approval For ... showing significant improvement in progression-free survival compared to chemotherapy. Vandana Singh NuCana's Encouraging Data From Resistant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...

Ten Times to Try Telehealth from Trusted Medical Reference: MerckManuals.com RAHWAY, N.J., September 10, 2024 – Merck Manuals, an authoritative online medical reference, shares advice from experts on ...

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

A Merck & Co. effort to move its PD-1 behemoth ... On the study’s primary endpoint of recurrence-free survival, Keytruda missed the mark in preventing disease recurrence or death compared ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck KGaA has been working with data analytics technologies Palantir Technologies on digital tools for health and life sciences since 2017, and the fruits of those labours are now being made ...